Yahoo · Sep 23, 2026
Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
TG
NASDAQ · TGTX
TG Therapeutics, Inc.
Healthcare · Biotechnology
$53.91
Down-$1.72 (-3.19%)
Updated Oct 6, 2026, 11:56 PM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- 77.67
- Dividend yield
- 0.00%
- 52-week range
- $26.76 – $59.30
- Volume
- 1.55M
- Avg. volume
- 1.87M
Price performance · TGTX
TGTX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
TGTX closed at $53.91 after 20 trading sessions, down 3.28% for the selected period.
- Last close
- $53.91
- Period change
- -3.28%
- Period low
- $53.04
- Period high
- $58.11
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $54.35 | $54.75 | $53.321 | $53.91 | 1.55M |
| Oct 2, 2026 | $54.17 | $54.98 | $53.145 | $54.29 | 1.65M |
| Oct 1, 2026 | $55.58 | $56.12 | $53.59 | $53.62 | 2.12M |
| Sep 30, 2026 | $56.41 | $56.98 | $55.3554 | $55.78 | 1.91M |
| Sep 29, 2026 | $56.04 | $56.68 | $54.7901 | $56.19 | 1.61M |
| Sep 28, 2026 | $57.35 | $57.66 | $55.88 | $56.19 | 1.44M |
| Sep 25, 2026 | $57.97 | $58.69 | $56.61 | $57.43 | 1.31M |
| Sep 24, 2026 | $55.95 | $57.55 | $55.09 | $57.52 | 1.14M |
| Sep 23, 2026 | $58.11 | $58.25 | $54.78 | $56.00 | 2.12M |
| Sep 22, 2026 | $57.41 | $58.62 | $56.56 | $58.11 | 2.08M |
| Sep 21, 2026 | $57.23 | $58.92 | $56.00 | $57.16 | 2.14M |
| Sep 18, 2026 | $56.98 | $57.73 | $56.18 | $56.87 | 5.17M |
| Sep 17, 2026 | $57.61 | $57.87 | $56.0401 | $56.47 | 1.47M |
| Sep 16, 2026 | $53.12 | $57.605 | $53.105 | $55.85 | 2.35M |
| Sep 15, 2026 | $53.59 | $54.4124 | $52.5001 | $53.04 | 1.76M |
| Sep 14, 2026 | $53.97 | $54.20 | $53.19 | $54.00 | 1.36M |
| Sep 11, 2026 | $55.71 | $56.26 | $53.47 | $53.89 | 1.37M |
| Sep 10, 2026 | $54.36 | $55.41 | $54.01 | $55.39 | 1.37M |
| Sep 9, 2026 | $55.55 | $57.14 | $54.24 | $54.65 | 1.41M |
| Sep 8, 2026 | $55.34 | $55.925 | $54.09 | $55.74 | 1.09M |
Latest TGTX news
The latest Smart Investors Daily articles mentioning TGTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TGTX research
Overview
Company profile and research snapshot.
Company profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $60.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 27, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 7, 2026 | B of A Securities | Underperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
ChartMill · Sep 21, 2026
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup
TGTX pairs strong growth with a tightening base below resistance. See ChartMill’s breakout setup, key levels, risks, and position sizing.
Yahoo · Sep 18, 2026
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. Spea
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
